Microsoft word - formd_e_2007.doc

United Nations Convention against Illicit Traffic
In Narcotic Drugs and Psychotropic Substances of 1988
ANNUAL INFORMATION ON SUBSTANCES FREQUENTLY
USED IN THE ILLICIT MANUFACTURE OF NARCOTIC DRUGS
AND PSYCHOTROPIC SUBSTANCES
United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988: article 12, paragraph 12 Economic and Social Council resolution 1995/20 Country or territory ________________________________________ Date Competent authority (for article 12 of the 1988 Convention) Name __________________________________________________ (Signature) Title or function This information relates to the calendar year 20____ Please, fill in the form carefully and complete it in a clear manner, including the information requested in this Cover Page.
This report, IN A SINGL E COPY, should be sent to
the INTERNATIONAL NA
RCOTICS CONTROL BOARD
SEIZURES OF SUBSTANCES IN TABLES I AND II Ephedrine raw material a
Ephedrine preparations a
SEIZURES OF SUBSTANCES IN TABLES I AND II (continued) SEIZURES OF SUBSTANCES IN TABLES I AND II (continued) Pseudoephedrine raw material a
Pseudoephedrine preparations a
If necessary, use conversion factors on page 21. Included by decision of the Commission on Narcotic Drugs at its forty-third session in 2000. That decision was communicated by the Secretary-General to all States on 15 May 2000, becoming effective on 11 November 2000. Figures included in this form should be expressed in terms of pure content of the respective base, salt or preparation, not including weight of packages or containers.
SUBSTANCES NOT INCLUDED IN TABLES I OR II IDENTIFIED AS HAVING BEEN USED IN ILLICIT MANUFACTURE Available information to be brought to the attention of the Board, which may include: the total quantity seized; the number of seizures and the quantity seized by country of origin; circumstances and place of seizure (e.g. in illicit laboratories, commercial warehouses or customs area, etc.); the name of the narcotic drug or psychotropic substance that was intended to be illicitly manufactured using the volume and extent of the illicit manufacture of the above narcotic drug or psychotropic substance; licit use of the substance seized including extent, importance, etc.; transit country (where applicable); destination country (where different from reporting country). Please continue on separate sheet(s) if necessary METHODS OF DIVERSION AND ILLICIT MANUFACTURE A. Methods of diversion and illicit manufacture
Please supply detailed information on methods of diversion and illicit manufacture, particularly in relation to, where appropriate, the more significant cases reported on pages 2 to 6 (i.e. cases involving seizures of substances scheduled in Tables I and II, and cases involving seizures of substances not scheduled in Table I or II but identified as having been used in illicit manufacture). For scheduled substances this additional information may include: whether or not a seized substance was actually intended for illicit manufacture of drugs (e.g. a seizure might have been effected because of lack of a valid import permit, but subsequent investigations might have shown that the substance was being imported for legitimate purposes); circumstances and place of seizure (e.g. in illicit laboratories, commercial warehouses or customs area, etc.); the name of the narcotic drug or psychotropic substance that was intended to be illicitly manufactured using the transit country (where applicable); destination country (where different from reporting country). Please continue on separate sheet(s) if necessary B. Information on stopped shipments
Parties are obliged under article 12, paragraph 9 (c), to notify, as soon as possible, the competent authorities and services of the Parties concerned if there is reason to believe that the import, export or transit of a substance in Table I or Table II is destined for the illicit manufacture of narcotic drugs or psychotropic substances. Information on shipments that have been stopped because of sufficient evidence that the substance may be diverted into illicit channels, is essential to overview trafficking trends, and to prevent attempts to divert the substances from other sources. Countries are therefore requested to provide detailed information on stopped shipments of substances scheduled in Tables I and II and of non-scheduled substances. This information may include, in particular: circumstances which raised suspicion about the shipment; countries/territories informed of the stopped shipment; Please continue on separate sheet(s) if necessary ANNUAL INFORMATION ON LICIT TRADE IN, AND USE OF, SUBSTANCES LISTED IN TABLE I OF This information is requested on a voluntary basis in accordance with resolution 1995/20 of the Economic and Social Council, which, inter alia: “Urges Governments… to inform the Board on a regular basis, upon request of the Board and in the form and manner provided for by it, of the quantities of substances listed in Table I of the 1988 Convention that they have imported, exported or transshipped, and encourages them to estimate their annual licit needs” (paragraph 8); “ Requests the Board… to collect information pursuant to paragraph 8 above, and to further develop and strengthen its database in order to assist Governments in preventing diversion of substances listed in Table I of the 1988 Convention…” (paragraph 9). In accordance with Resolution 49/3 of the Commission on Narcotic Drugs (CND) entitled “Strengthening systems for the control of precursor chemicals used in the manufacture of synthetic drugs”, which, inter alia: “Requests Member States to provide to the International Narcotics Control Board annual estimates of their legitimate requirements for 3,4 methylenedioxypehnyl-2-propanone, pseudoephedrine, ephedrine and phenyl—2-propanoneand, to the extent possible, estimated requirements for imports of preparations containing those substances that can be easily used or recovered by readily applicable means” (paragraph 1) 1. If unable to provide data in detail, please provide partial information as far as possible. Where appropriate, please indicate “none” (no trade has taken place, or there is no current licit use or need), or “unknown”. 2. Please specify where the information should be treated CONFIDENTIALLY.
A. Licit trade
Ephedrine raw material a
Ephedrine preparations a
raw material a
preparations a
* If exact quantity by country(ies) of origin/destination is not available, please provide approximate total quantity. a Figures included in this form should be expressed in terms of pure content of the respective base, salt or preparation, not including weight of packages or containers.
Please continue on separate sheet(s) if necessary. B. Licit uses and needs
For what licit purposes are Table I substances used in your country/territory: B. Licit uses and needs (continued) For what licit purposes are Table I substances used in your country/territory: Please continue on separate sheet(s) if necessary B. Licit uses and needs (continued) For what licit purposes are Table I substances used in your country/territory: B. Licit uses and needs (continued) For what licit purposes are Table I substances used in your country/territory: Please continue on separate sheet(s) if necessary. C. Annual information on licit trade in, and use of, substances listed in Table II
of the 1988 Convention

The Economic and Social Council, in its resolution 1995/20 also “Encourages Governments to consider strengthening,
where necessary, the working mechanisms to prevent diversion of substances listed in Table II of the 1988 Convention, as
described in the resolution” (present paragraph 13). Where Governments wish to strengthen existing mechanisms to
prevent diversion of Table II substances, it is important that they also collect information on the licit trade in, and use of,
those substances. The Governments concerned are invited to submit to the Board available information on such licit trade
and use, in order to enable it to assist Governments further in preventing diversion of such substances. Please specify
where information should be treated CONFIDENTIALLY.
Information on the following substances may be provided: acetone, anthranilic acid, ethyl ether, hydrochloric acid, methyl
ethyl ketone, phenylacetic acid, piperidine, sulphuric acid, toluene.
Substance (please specify) __________________________________

Imports (by country(ies) of origin): Exports (by country(ies) of destination): Licit purposes for which the substance is used, and estimated annual needs (quantity): Substance (please specify) __________________________________ Imports (by country(ies) of origin): Exports (by country(ies) of destination): Licit purposes for which the substance is used, and estimated annual needs (quantity): Substance (please specify) __________________________________ Imports (by country(ies) of origin): Exports (by country(ies) of destination): Licit purposes for which the substance is used, and estimated annual needs (quantity): Substance (please specify) __________________________________ Imports (by country(ies) of origin): Exports (by country(ies) of destination): Licit purposes for which the substance is used, and estimated annual needs (quantity): Substance (please specify) __________________________________ Imports (by country(ies) of origin): Exports (by country(ies) of destination): Licit purposes for which the substance is used, and estimated annual needs (quantity): Substance (please specify) __________________________________ Imports (by country(ies) of origin): Exports (by country(ies) of destination): Licit purposes for which the substance is used, and estimated annual needs (quantity): Substance (please specify) __________________________________ Imports (by country(ies) of origin): Exports (by country(ies) of destination): Licit purposes for which the substance is used, and estimated annual needs (quantity): Substance (please specify) __________________________________ Imports (by country(ies) of origin): Exports (by country(ies) of destination): Licit purposes for which the substance is used, and estimated annual needs (quantity): Please continue on separate sheet(s) if necessary To allow for proper comparison of collected information it is important that all data are collated in a standardized format. To
simplify the necessary standardization process, figures should be given in grams or kilograms where the substance is a
solid, and in litres where the substance (or its most common form) is a liquid.
Seizures of solids reported in litres should not be converted into kilograms, since the actual quantity of the substance in the
solution will not be known.
For seizures of liquids, quantities reported in kilograms should be converted into litres using the following factors:
Isosafrole 0.892 3,4-Methylenedioxy-phenyl-2-propanone 0.833 Methyl ethyl ketone 1-Phenyl-2-propanone 0.985 Safrole 0.912 Sulphuric acid (concentrated solution) Derived from density, quoted in The Merck Index, 11th edition, Merck and Co., Inc., United States of America, 1989. For example, to convert 1,000 kilograms of methyl ethyl ketone into litres, multiply by 1.242, i.e. 1,000 x 1.242 = 1,242 litres. To facilitate the collection of information from trade statistics, the Harmonized System (HS) codes of the World Customs Organization are given below: Substance HS 3,4-Methylenedioxy-phenyl-2-propanone 2932.92

Source: http://hemikalii.com.mk/dokumenti_o/16_443773956.pdf

jol.liljenzin.se

Contents Solvent extraction is a technique which has been highly developed within many nationalnuclear energy programs because of its suitability as a selective separation process for fissionproducts, actinides, and other radioactive substances. The technique is briefly described inseveral sections of this book (§§ 5.5.3, 9.2.6, 9.4.3, 15.7.4, 16.3.3, 21.7, and especially in21.6 on the Purex

lyc-louis-armand.fr

BIOGRAPHIE Raphaël Poulain né l est un joueur professionnel dequi a évolué au poste (1,86 m, 100 kg) aupendant 7 ans de 1998 à 2005 puis aupour la saison 2007-2008. Après avoir suivi une formation de coach mental, il a entrepris des études de philosophie et de psychologie à l'EEPPA. Il se consacre aujourd'hui essentiellement au métier d'acteur. Considéré comme un tr

© 2010-2018 PDF pharmacy articles